Archives

Choose a date range

From To

Choose one or more categories

Categories:



 


Genentech to acquire Seragon Pharmaceuticals

Wednesday, July 2, 2014 12:38 PM

Genentech, a member of the Roche Group, will acquire Seragon Pharmaceuticals, a privately held biotechnology company based in San Diego, Calif. Genentech obtains rights to Seragon’s entire portfolio of investigational next-generation oral selective estrogen receptor degraders (SERDs) for the potential treatment of hormone receptor-positive breast cancer. 

More... »

WIRB Copernicus Group

Bellerophon Therapeutics names Jonathan Peacock chairman and CEO

Wednesday, July 2, 2014 11:37 AM

Bellerophon Therapeutics, a clinical stage biotherapeutics company, has announced that Jonathan Peacock has been appointed chairman and CEO. Peacock assumes the role from Daniel Tasse, chairman and CEO of Ikaria, who was interim chairman and CEO of Bellerophon since the company's spin-out from Ikaria in February. Tasse will continue as a member of the board of Bellerophon.

More... »

CRF Health eCOA webinar series

Amgen receives FDA Breakthrough Therapy Designation for Blinatumomab in ALL

Wednesday, July 2, 2014 11:04 AM

The FDA has granted Breakthrough Therapy Designation to Amgen’s investigational bispecific T cell engager (BiTE) antibody blinatumomab, for adults with Philadelphia-negative (Ph-) relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL), a rapidly progressing cancer of the blood and bone marrow.

More... »

Paratek Pharmaceuticals, Transcept Pharaceuticals to merge

Tuesday, July 1, 2014 02:51 PM

Transcept Pharmaceuticals of Point Richmond, Calif., and Boston-based Paratek Pharmaceuticals, a privately held biopharmaceutical company, have agreed to merge, with Paratek stockholders becoming the majority owners of Transcept. The operations of the two companies will be combined and the new entity will be named Paratek Pharmaceuticals.

More... »

Actavis completes Forest Laboratories acquisition

Tuesday, July 1, 2014 10:50 AM

Dublin-based Actavis has completed its acquisition of Forest Laboratories in a cash and equity transaction valued at approximately $28 billion. The combination creates a specialty pharmaceutical company with annual revenues of more than $15 billion anticipated for 2015.

More... »

The CenterWatch Monthly, July 2014

Tuesday, July 1, 2014 07:00 AM

IRB market consolidating rapidly

More... »

Philips, salesforce.com ink agreement for cloud-based healthcare information technology

Monday, June 30, 2014 03:40 PM

Royal Philips, a healthcare technology company, and salesforce.com, a provider of customer relationship management software, have announced a strategic alliance to deliver an open, cloud-based healthcare platform, leveraging Philips' medical technology, clinical applications and clinical informatics and salesforce.com's experience in enterprise cloud computing, innovation and customer engagement.

More... »

India’s generics industry hires consultant to boost image

Monday, June 30, 2014 03:38 PM

Companies specializing in generic pharmaceuticals in India and the U.S. have retained India First Group to promote the benefits of affordable access to medicine as vital to improving healthcare worldwide. India First Group is a strategic advisory firm based in Washington, D.C. and New Delhi that assists U.S. companies pursuing business opportunities in India and supports Indian companies investing in the U.S.

More... »

Trovagene inks agreement with Lurie Comprehensive Cancer Center, NMDTI

Monday, June 30, 2014 03:35 PM

Trovagene has partnered with the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and the Northwestern Medicine Developmental Therapeutics Institute (NMDTI) to conduct a translational research program designed to assess the utility of Trovagene's urine-based cell-free oncogene mutation monitoring technology in clinical practice.

More... »

Chesapeake Urology raises $100,000 for Urology Care Foundation

Monday, June 30, 2014 03:34 PM

Sanford Siegel, M.D., president and CEO of Chesapeake Urology Associates, presented the Urology Care Foundation with $114,248 in support of its prostate cancer research efforts. The funds were raised through the Zero Prostate Cancer Challenge (ZPCC) 10K/5K run in September 2013. The Urology Care Foundation is the official foundation of the American Urological Association (AUA)—an organization of roughly 20,000 urologists.

More... »

CenterWatch Drugs in Clinical Trials
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

July 21

As job growth in drug development sector soars, more employees are seeking new opportunities

U.K. study: Prisoners should have the right to participatein clinical trials on moral grounds, for healthcare access

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

CRO market poised for growth and consolidation
Sponsors expanding pipelines, shrinking infrastructure fuel strategic outsourcing

Strategies for success evolving in phase I space
Sites see increasing complexity, more patients, greater focus on efficacy

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs